SRRK - Scholar Rock Inc. Total Debt to Capital
This chart of current Scholar Rock (SRRK) quotes on GURU.Markets reflects a debt-to-equity ratio of 0.82. The business relies on the expansion of apitegromab to combat SMA. A team of leading biologists is developing neurological drugs, driven by a mission to save lives. Innovative methods for muscle recovery in cases of fibrosis and atrophy are currently undergoing active trials.
%20-%20All%20Debt%20to%20Shareholders'%20Equity%20Ratio&width=1200&height=400&colorIndex=0&v=mvvwvvs9.gq-7b28iyo&start=20220704&end=20261031&filename=GURU_Markets_-_SRRK_-_Scholar-Rock_-_All-Debt-to-Shareholders-Equity-Ratio "SRRK (Scholar Rock) Total Debt to Capital history from 07/04/2022 to 10/31/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Scholar Rock
This ratio is calculated as the ratio of total liabilities to equity, determining the business's degree of reliance on borrowed funds within its financing structure. By analyzing changes in the total debt-to-equity ratio, investors assess the financial stability of Scholar Rock (SRRK) amid stringent FDA oversight and the colossal costs associated with developing proprietary monoclonal antibodies.